About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker CANF · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Feb 18, 2026An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe…
NCT07410455 · Lowe Syndrome
Piclidenoson
CANF
Can-Fite BioPharma
Phase 2Not yet recruiting5Aug 31, 2027Registry ↗
Apr 29, 2025A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Effica…
NCT06643260 · Plaque Psoriasis
piclidenoson, Placebo
CANF
Can-Fite BioPharma
Phase 3Not yet recruiting705Dec 2027Registry ↗
Apr 29, 2025Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class…
NCT05201404 · Hepatocellular Carcinoma, Cirrhosis
Namodenoson, Placebo
CANF
Can-Fite BioPharma
Phase 3Recruiting471Feb 2026Registry ↗
Jan 31, 2025Namodenoson Treatment of Advanced Pancreatic Cancer
NCT06387342 · Pancreatic Adenocarcinoma, Pancreatic Cancer
Namodenoson 25mg
CANF
Can-Fite BioPharma
Phase 2Recruiting20Jul 15, 2026Registry ↗
Jul 31, 2024Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
NCT04697810 · NASH - Nonalcoholic Steatohepatitis
Namodenoson, Placebo
CANF
Can-Fite BioPharma
Phase 2Unknown114Apr 15, 2025Registry ↗
Sep 18, 2023Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients
NCT00280917 · Rheumatoid Arthritis
CF101
CANF
Can-Fite BioPharma
Phase 2Completed254Apr 2007Registry ↗
Feb 8, 2023Safety and Efficacy Study of CF101 to Treat Psoriasis
NCT00428974 · Plaque Psoriasis
CF101 1mg, CF101 2mg
CANF
Can-Fite BioPharma
Phase 2Completed76Sep 2009Registry ↗
Oct 4, 2022Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepato…
NCT02128958 · Hepatocellular Carcinoma
CF102, Placebo
CANF
Can-Fite BioPharma
Phase 2Completed78Nov 27, 2017Registry ↗
Jun 30, 2022Trial of CF101 to Treat Patients With Dry Eye Disease
NCT01235234 · Keratoconjunctivitis Sicca
CF101
CANF
Can-Fite BioPharma
Phase 3Completed236Nov 2013Registry ↗
Jun 28, 2022CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis
NCT03168256 · Plaque Psoriasis
CF101 2mg, CF101 3mg
CANF
Can-Fite BioPharma
Phase 3Completed528Jan 6, 2022Registry ↗
May 24, 2022Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis
NCT01034306 · Rheumatoid Arthritis
CF101, Placebo control
CANF
Can-Fite BioPharma
Phase 2Completed79Dec 2013Registry ↗
May 17, 2022A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
NCT00790218 · Hepatocellular Carcinoma
CF102
CANF
Can-Fite BioPharma
Phase 1/2Completed19Dec 2012Registry ↗
May 12, 2022Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressu…
NCT01033422 · Ocular Hypertension, Glaucoma
CF101, Placebo for
CANF
Can-Fite BioPharma
Phase 2Completed89Dec 2016Registry ↗
May 9, 2022Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
NCT00349466 · Keratoconjunctivitis Sicca
CF101, Placebo
CANF
Can-Fite BioPharma
Phase 2Completed80May 2009Registry ↗
Apr 22, 2022Piclidenoson for Treatment of COVID-19
NCT04333472 · COVID-19, Coronavirus Infection
Piclidenoson, Placebo
CANF
Can-Fite BioPharma
Phase 2Completed6Mar 6, 2022Registry ↗
Dec 19, 2020CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis
NCT02647762 · Rheumatoid Arthritis
CF101 1 mg, CF101 2 mg
CANF
Can-Fite BioPharma
Phase 3Terminated244Nov 30, 2020Registry ↗
Nov 18, 2020Trial of CF101 to Treat Patients With Psoriasis
NCT01265667 · Plaque Psoriasis
CF101, Placebo
CANF
Can-Fite BioPharma
Phase 2/3Completed293Mar 2015Registry ↗
Mar 17, 2020A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
NCT02927314 · Non-alcoholic Steatohepatitis (NASH)
CF102, Placebo
CANF
Can-Fite BioPharma
Phase 2Completed60Mar 1, 2020Registry ↗
Mar 29, 2018Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients
NCT00556894 · Rheumatoid Arthritis
CF101, Placebo
CANF
Can-Fite BioPharma
Phase 2Completed253Mar 2009Registry ↗
Feb 1, 2018Safety &Efficacy of CF101 to Subjects With Uveitis
NCT01905124 · Uveitis, Posterior, Uveitis, Intermediate
CF101, Placebo
CANF
Can-Fite BioPharma
Phase 2Withdrawn0Sep 2019Registry ↗
Feb 1, 2018A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee
NCT00837291 · Osteoarthritis of the Knee
CF101, Placebo
CANF
Can-Fite BioPharma
Phase 2Withdrawn0Dec 2018Registry ↗
Apr 15, 2015A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1
NCT00790673 · Chronic Hepatitis C
CF 102, Placebo
CANF
Can-Fite BioPharma
Phase 1/2Completed32Jun 2011Registry ↗

22 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:27 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances